Department of Structural and Chemical Biology, Mount Sinai School of Medicine, 1425 Madison Avenue, Box 1677, New York, NY 10029, USA.
Methods. 2011 Jan;53(1):97-101. doi: 10.1016/j.ymeth.2010.09.001. Epub 2010 Sep 7.
Human immunodeficiency virus (HIV) when integrated into a host chromosome exists in a transcriptionally inactive but replication-competent state. Such latent infection represents a major challenge to HIV eradication efforts because a permanent virus reservoir resided in the infected cell is able to spike the viral load on immune suppression or during interruption of highly active anti-retroviral therapy. Understanding the molecular mechanisms that control HIV proviral latency and its reactivation could provide new perspectives on host factors as therapeutic targets for abolishing cellular reservoirs of dormant HIV. Although the control of HIV latency is multifactorial, chromatin structure and the chromatin-associated transcriptional machinery are known to be important factors. For instance, transcription initiation of the HIV provirus involves a complex molecular interplay between chromatin-associated proteins and the virus-encoded trans-activator, Tat. The first part of this review discusses our current understanding of the elements involved in HIV transcriptional activation and viral mRNA elongation, mainly post-translational modifications of HIV Tat and its interactions with host chromatin-modifying enzymes and chromatin-remodeling complexes. The second part highlights new experimental therapeutic approaches aimed at administrating activators of HIV gene expression to reduce or eliminate the pool of latently HIV-infected cells.
人类免疫缺陷病毒(HIV)整合到宿主染色体中时,处于转录非活跃但复制有活性的状态。这种潜伏感染是 HIV 根除工作的主要挑战,因为感染细胞中存在的永久性病毒库能够在免疫抑制或高效抗逆转录病毒治疗中断期间使病毒载量激增。了解控制 HIV 前病毒潜伏和重新激活的分子机制,可以为宿主因素提供新的视角,作为消除潜伏 HIV 细胞库的治疗靶点。尽管 HIV 潜伏期的控制是多因素的,但染色质结构和与染色质相关的转录机制是已知的重要因素。例如,HIV 前病毒的转录起始涉及到染色质相关蛋白和病毒编码的反式激活因子 Tat 之间的复杂分子相互作用。本文的第一部分讨论了我们目前对 HIV 转录激活和病毒 mRNA 伸长涉及的因素的理解,主要是 HIV Tat 的翻译后修饰及其与宿主染色质修饰酶和染色质重塑复合物的相互作用。第二部分重点介绍了旨在减少或消除潜伏 HIV 感染细胞池的新的实验性治疗方法,即通过给予 HIV 基因表达的激活剂来实现。